Added Webcast and Presentation Slides to Public Workshop – Adapting Regulatory Oversight of Next Generation Sequencing-Based Tests

The Food and Drug Administration announced the following public workshop entitled: “Adapting Regulatory Oversight of Next Generation Sequencing-Based Tests”. The purpose of this workshop was to obtain feedback on two FDA draft guidances, “Use of Standards in FDA Regulatory Oversight of Next Generation Sequencing (NGS)-Based In Vitro Diagnostics (IVDs) Used for Diagnosing Germline Diseases” and…

Emergency Use Authorizations: Zika Virus Detection by RT-PCR Test (ARUP Laboratories)

On February 26, 2016, the FDA issued an Emergency Use Authorization (EUA) to authorize the emergency use of Centers for Disease Control and Prevention’s (CDC) Zika Immunoglobulin M (IgM) Antibody Capture Enzyme-Linked Immunosorbent Assay (Zika MAC-ELISA) for the presumptive detection of Zika virus-specific IgM in human sera or cerebrospinal fluid (CSF) that is submitted alongside…

FDA Voice blog: Using Symbols to Convey Information in Medical Device Labeling

By: Antoinette (Tosia) Hazlett, MSN, RN, and Scott Colburn CAPT, USPHS Symbols convey important messages for navigating everyday life; whether it’s a traffic sign or a graphic image indicating that no smoking is allowed in a building. Symbols in medical device labeling can also convey important information. However, to be an effective means of communicating…

Information on the Artificial Pancreas Device System

<!– –> <!– Page Last Updated: 09/28/2016 –> Page Last Updated: 09/28/2016 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.

Consumer Information on: The 670G System

This is a brief overview of information related to FDA’s approval to market this product. See the links below to the Summary of Safety and Effectiveness Data (SSED) and product labeling for more complete information on this product, its indications for use, and the basis for the FDA’s approval. Product Name: The 670G SystemPMA Applicant:…

Updated the Expedited Access Pathway Program website with two Data Development Plan Examples

The Expedited Access Pathway (EAP) program is a voluntary program for certain medical devices that demonstrate the potential to address unmet medical needs for life threatening or irreversibly debilitating diseases or conditions that are subject to premarket approval applications (PMA) or are eligible for de novo requests. The program is detailed in the FDA’s guidance…